St. Jude Medical
St. Jude Medical EnligHTNment Study Highlighted at EuroPCR During Trials That May Change Clinical Practice Session
May 21, 2013 9:52 am | by The Associated Press | News | CommentsST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--May 21, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the start of its landmark EnligHTNment clinical study. This is the largest randomized, prospective trial to determine whether renal denervation and...
St. Jude Medical Announces First Patient Enrollment in EnligHTN III Renal Denervation Study of Next-Generation EnligHTN System
May 14, 2013 8:00 am | by The Associated Press | News | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--May 14, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced enrollment of the first patient in the EnligHTN III trial. This study will evaluate the safety and performance of the new second-generation EnligHTN ™ Renal...
St. Jude Medical Announces Results from Independent Analysis of Optim-Insulated Defibrillation Leads in Late-Breaking Clinical Trial Session at Heart Rhythm 2013
May 9, 2013 1:55 pm | by The Associated Press | News | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--May 9, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the Population Health Research Institute (PHRI), an academic health science research institute, has conducted a further independent analysis of data received from...
St. Jude Medical Announces CE Mark Approval of Next-Generation Ellipse and SJM Assura High Voltage Devices
May 8, 2013 8:00 am | by The Associated Press | News | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--May 8, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced CE Mark approval of its next-generation Ellipse™ and SJM Assura™ portfolio of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy...
St. Jude Medical Enrolls First Patient in Next-Generation Quadra Study
May 3, 2013 9:46 am | by Business Wire | News | CommentsSt. Jude Medical, a global medical device company, today announced first enrollment of its MultiPoint Pacing clinical study to build upon its first- to-market Quadripolar Pacing System. Patients will be implanted with the Quadra Assura MP cardiac resynchronization therapy defibrillator (CRT-D) and Quartet lead to assess pacing in multiple locations in the heart.
Patients Slap St. Jude Medical with Lawsuits over Recalled Riata Heart Wires
April 5, 2013 2:27 pm | by Mass Device | News | CommentsSt. Jude Medical was slapped with multiple lawsuits in California courts yesterday over its recalled Riata defibrillator lead, alleging that the heart wires were defective and led to injuries or death for more than 30 patients. The lawsuits generally accuse St. Jude of violating both state and federal requirements for reporting issues with medical devices...
Will Another Durata Failure Report Drag St. Jude Down?
March 28, 2013 1:31 pm | by Mass Device | News | CommentsWall Street didn't move much on news of another insulation-related failure in St. Jude Medical's next-generation Durata defibrillator leads this week. The case report included a detailed analysis of an incident in which a Durata lead failed due to inside-out abrasion...
Results of St. Jude Medical's RESPECT Trial Published in The New England Journal of Medicine
March 20, 2013 5:08 pm | by The Associated Press | News | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--Mar 20, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced publication of results from its landmark RESPECT trial in The New England Journal of Medicine. The study results show that device closure using the AMPLATZER™ PFO...
St. Jude Medical launches Ilumien Optis in Japan
March 12, 2013 10:03 am | by Mass Device | News | CommentsSt. Jude Medical (NYSE:STJ) said its launched the Ilumien Optis device in Japan, calling it the only medical device on the market to combine fractional flow reserve and optical coherence tomography technology to allow doctors to evaluate the state and severity of coronary lesions.
St. Jude Medical Announces Launch of 3D Vessel Reconstruction Technology in Japan
March 11, 2013 8:00 am | by The Associated Press | News | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--Mar 11, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the launch of its ILUMIEN ™ OPTIS ™ System, a next-generation technology designed to help physicians make personalized stenting decisions based on each patient’s...
St. Jude Medical Announces First Implant in Pivotal Phase of Clinical Trial Evaluating AMPLATZER Cardiac Plug for the Prevention of Stroke in Patients with Atrial Fibrillation
March 8, 2013 8:00 am | by The Associated Press | News | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--Mar 8, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the first patient implant in a new pivotal trial evaluating the company’s AMPLATZER ™ Cardiac Plug (ACP) for the prevention of stroke. The AMPLATZER ™ Cardiac Plug...
St. Jude Medical to Present at the Barclays Global Healthcare Conference
February 27, 2013 4:20 pm | by The Associated Press | News | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--Feb 27, 2013--St. Jude Medical, Inc. (NYSE:STJ) will present at the Barclays Global Healthcare Conference on Tuesday, March 12, in Miami. John Heinmiller, executive vice president, will address the conference at 10:15 a.m. EDT. The presentation will also be...
Study: 1 in 10 Recalled St. Jude Medical Riata Lead Coatings Fail Within Six Years
February 25, 2013 2:43 pm | by Mass Device | News | CommentsDanish researchers reported this week that their latest studies of St. Jude Medical's recalled Riata defibrillator leads found that 1 in 10 had poked through their coating in an average of just over 5 years. The study included 298 Danish patients, representing "virtually every living patient in Denmark who received Riata defibrillator leads," according to Heartwire.
St. Jude Looks Beyond Blood Pressure for Benefits of Renal Denervation
February 15, 2013 12:06 pm | by Mass Device | News | CommentsSt. Jude Medical is aiming to take its renal denervation therapy a step further, looking for signs that the minimally invasive treatment improves health beyond lowering high blood pressure in patients with uncontrolled hypertension. The company's new Enlightnment trial is looking for long-term effects of renal denervation therapy...
Device Tax: We Need Action by Summer, Paulsen Says
February 4, 2013 3:43 pm | by Mass Device | News | CommentsMedical device industry advocate Rep. Erik Paulsen (R-Minn.) says Congress needs to act on the medical device tax by "late spring, early summer" this year. Rep. Erik Paulsen (R-Minn.), an unrelenting opponent of the medical device tax that took effect at the start of the year, still sees avenues for repeal tied to larger discussions of corporate tax reform. News Well, Capitol Hill, Medical Device Taxread more
Continuous spinal cord stimulation improves heart function
August 27, 2012 9:21 am | by European Society of Cardiology | News | CommentsSpinal cord stimulation improves heart function and could become a novel treatment option for heart failure, according to research presented at the ESC Congress 2012 today by Professor Hung-Fat Tse from Hong Kong. Heart failure is a progressive weakening of the heart muscle. It is a chronic condition that occurs when the heart cannot pump blood to meet the body’s needs.
St. Jude Medical Announces Next-Generation PressureWire for FFR Measurement
March 23, 2012 10:50 am | News | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc., a global medical device company, today announced it has received U.S. Food and Drug Administration (FDA) clearance for multiple enhancements to its PressureWireâ„¢ Fractional Flow Reserve (FFR) measurement guidewire.
Independent Data Safety Monitoring Board Recommends St. Jude Medical's FAME II Clinical Trial Stop Enrollment Following Positive Interim Analysis
January 19, 2012 5:13 am | News | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, announced today that an interim analysis of the FAME II trial has found a highly statistically significant reduction in the need for hospital readmission and urgent revascularization when...
Data from St. Jude Medical's ASSERT Implantable Device Monitoring Study Published in New England Journal of Medicine
January 13, 2012 5:26 am | News | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, a global medical device company, today announced the publication of results from the ASSERT cohort study in the New England Journal of Medicine (NEJM). The ASSERT study, or ASymptomatic AF and Stroke Evaluation...
Parkinson treatment shows positive results in clinical testing
January 11, 2012 5:09 am | News | CommentsGAINESVILLE, Fla. - Researchers from the University of Florida and 14 additional medical centers reported results today in the online version of The Lancet Neurology journal indicating that deep brain stimulation - also known as DBS - is effective at improving motor symptoms...
St. Jude Medical Announces First Implant in European Clinical Trial Studying Portico Transcatheter Aortic Heart Valve
December 14, 2011 4:14 am | News | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the first implant of its Porticoâ„¢ transcatheter aortic valve implant (TAVI) in a European clinical trial to support CE Mark approval. The trial will study the safety and effectiveness...
Study Determines FFR Can Improve Health while Reducing Economic Burden to Belgian Health Care System
December 14, 2011 4:03 am | News | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc., a global medical device company, today announced that an analysis of the benefits of using a Fractional Flow Reserve (FFR)-guided intervention in Belgium to determine the severity of blood flow blockages in patients' coronary arteries...
St. Jude Medical Announces FDA Approval of Industry's First Quadripolar Pacing System
December 1, 2011 6:07 am | News | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc., a global medical device company, today announced it has received U.S. Food and Drug Administration (FDA) approval of its Unify Quadra® cardiac resynchronization therapy defibrillator (CRT-D) and Quartet® Left Ventricular Quadripolar Pacing Lead.
St. Jude Medical Portico Transcatheter Valve Demonstrates Promising Results in Feasibility Study
November 11, 2011 4:40 am | News | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the feasibility study results for the company's Porticoâ„¢ Transcatheter Aortic Heart Valve, presented at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
St. Jude Medical Expands Hospital Access to Wireless Fractional Flow Reserve Technology with New Agreement
November 9, 2011 4:32 am | News | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE: STJ), a global medical device company, today announced its wireless PressureWireâ„¢ Aeris technology, which aids in the diagnosis and treatment of coronary artery blockages by measuring Fractional Flow Reserve...
